Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Nociceptin inhibits cough in the guinea-pig by activation of ORL1 receptors
Autore:
McLeod, RL; Parra, LE; Mutter, JC; Erickson, CH; Carey, GJ; Tulshian, DB; Fawzi, AB; Smith-Torhan, A; Egan, RW; Cuss, FM; Hey, JA;
Indirizzi:
Schering Plough Corp, Res Inst, Allergy, Kenilworth, NJ 07033 USA ScheringPlough Corp Kenilworth NJ USA 07033 gy, Kenilworth, NJ 07033 USA Schering Plough Corp, Res Inst, CNS Biol, Kenilworth, NJ 07033 USA Schering Plough Corp Kenilworth NJ USA 07033 ol, Kenilworth, NJ 07033 USA Schering Plough Corp, Res Inst, Chem, Kenilworth, NJ 07033 USA Schering Plough Corp Kenilworth NJ USA 07033 em, Kenilworth, NJ 07033 USA
Titolo Testata:
BRITISH JOURNAL OF PHARMACOLOGY
fascicolo: 6, volume: 132, anno: 2001,
pagine: 1175 - 1178
SICI:
0007-1188(200103)132:6<1175:NICITG>2.0.ZU;2-6
Fonte:
ISI
Lingua:
ENG
Soggetto:
IN-VITRO; ANTAGONIST; J-113397; FQ;
Keywords:
cough; ORL1 receptor; nociceptin; orphanin FQ; J113397;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
12
Recensione:
Indirizzi per estratti:
Indirizzo: McLeod, RL Schering Plough Corp, Res Inst, Allergy, 2015 Galloping Hill Rd, Kenilworth, NJ 07033 USA Schering Plough Corp 2015 Galloping Hill Rd Kenilworth NJ USA 07033
Citazione:
R.L. McLeod et al., "Nociceptin inhibits cough in the guinea-pig by activation of ORL1 receptors", BR J PHARM, 132(6), 2001, pp. 1175-1178

Abstract

We studied the central and peripheral antitussive effect of ORL1 receptor activation with nociceptin/orphanin FQ in conscious guinea-pigs. In guinea-pig cough studies, nociceptin/orphanin FQ (10, 30, and 90 mug) given directly into the CNS by an intracerebroventricular (i.c.v.) route inhibited cough elicited by capsaicin exposure by approximately 23, 29 and 52%, respectively. The antitussive activity of nociceptin/orphanin FQ (90 mug, i.c.v.) was blocked by the selective ORL1 antagonist [Phe(gamma)(1)(CH2-NH)Gly(2)]nociceptin-(1-13)-NH2 (180 mug, i.c.v.) and J113397 (10 mg kg(-1), i.p.) but not by the opioid antagonist, naltrexone (3 mg kg(-1), i.p.). Furthermore, intravenous (i.v.) nociceptin/orphanin FQ (1.0 and 3.0 mg kg(-1)) also inhibited cough approximately by 25 and 42%, respectively. These findings indicate that selective ORL1 agonists display the potential to inhibit cough by both a central and peripheral mechanism, and potentially represent a novel therapeutic approach for the treatment of cough.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 18/01/21 alle ore 06:00:59